<DOC>
	<DOCNO>NCT02194205</DOCNO>
	<brief_summary>To compare long-term ( one-year ) bronchodilator efficacy safety COMBIVENT hydrofluoroalkane ( HFA ) Inhalation Aerosol COMBIVENT chlorofluorocarbon ( CFC ) Inhalation Aerosol Placebo formulation patient COPD . In addition , steady state pharmacokinetics one dose interval follow four week therapy characterize .</brief_summary>
	<brief_title>Comparison Safety Efficacy COMBIVENT HFA COMBIVENT ( CFC ) Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>All patient must diagnosis COPD Male female patient 40 year age old Patients must smoke history ten packyears . A packyear defined equivalent smoke one pack 20 cigarette per day year Patients must able perform technically satisfactory pulmonary function test Patients must able trained proper use meter dose inhalator ( MDI ) All patient must sign Informed Consent Form prior participation trial i.e . prior prestudy washout usual pulmonary medication Patients must least one regular aerosol bronchodilator control COPD symptom symptom bronchospasm ( wheeze shortness breath ) present OR Patients must least two class prescribe bronchodilator regular basis control COPD symptom three month period immediately precede screen visit . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients clinically relevant abnormal baseline hematology , blood chemistry urinalysis . If abnormality defines disease list exclusion criterion , patient exclude All patient serum aspartate amino transferase ( ASAT/SGOT ) &gt; 80 IU/L , serum alanine amino transferase ( ALAT/SGPT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL creatinine &gt; 2.0 mg/dL exclude regardless clinical condition . Repeat laboratory evaluation conduct patient . Patients total bood eosinophil count &gt; = 600 mm**3 . A repeat eosinophil count conduct patient Patients recent history ( i.e . one year less ) myocardial infarction Patients recent history ( i.e . three year less ) heart failure patient cardiac arrhythmia require drug therapy Patients history cancer , treat basal cell carcinoma , within last five year Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis Patients undergone thoracotomy pulmonary resection . Patients wth history thoracotomy reason evaluate per exclusion criterion No . 1 Patients history asthma , allergic rhinitis atopy . Patients history active alcohol drug abuse Patients know active tuberculosis Patients upper respiratory tract infection COPD exacerbation six week prior Screening Visit ( Visit 1 ) baseline period Patients know symptomatic prostatic hypertrophy bladder neck obstruction Patients know narrowangle glaucoma Patients current significant psychiatric disorder Patients regular use daytime oxygen therapy Patients treat betablocker medication , monoamine oxidase ( MAO ) inhibitor tricyclic antidepressant Patients treat cromolyn sodium nedocromil sodium Patients treat antihistamines Patients use oral corticosteroid medication unstable dos dose excess equivalent 10 mg prednisone per day 20 mg every day Patients treat oral betaadrenergics longacting betaadrenergics two week prior Screening Visit baseline period Patients change therapeutic plan within last six week prior Screening Visit baseline period , exclude change long act oral betaadrenergics short act inhaled betaadrenergics purpose trial Pregnant nursing woman woman childbearing potential use medically approve mean contraception Patients know hypersensitivity anticholinergic betaagonist drug component either COMBIVENT formulation Patients take investigational drug within one month six half life ( whichever great ) prior Screening visit Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>